 NEW YORK, Oct. 6, 2021 PRNewswire -- BrainStorm Cell Therapeutics Inc. NASDAQ: BCLI, a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled CSF biomarker correlations with primary outcome in NurOwn Phase 3 clinical trial will be presented as a scientific poster at the fully digital 2021 Northeast Amyotrophic Lateral Sclerosis Consortium NEALS conference. The presentation will be delivered by James Berry, M.D. 